Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CervoMed ( (CRVO) ) has shared an update.
On July 28, 2025, CervoMed announced positive 32-week data from the Extension phase of the Phase 2b RewinD-LB trial, highlighting neflamapimod’s efficacy in slowing disease progression in patients with dementia with Lewy bodies (DLB). The trial results showed a significant reduction in the risk of clinical worsening and a decrease in plasma levels of a neurodegeneration biomarker, supporting the potential of neflamapimod as a transformative treatment for DLB. These findings were presented at the Alzheimer’s Association International Congress 2025, with plans to initiate a Phase 3 trial and discussions with the FDA later in the year.
The most recent analyst rating on (CRVO) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.
Spark’s Take on CRVO Stock
According to Spark, TipRanks’ AI Analyst, CRVO is a Neutral.
CervoMed’s primary challenges stem from its lack of revenue and persistent financial losses, which heavily weigh down its stock score. However, positive technical indicators and recent promising clinical trial results provide a speculative upside, balancing some of the financial concerns. Valuation remains a challenge due to negative earnings, but the potential for future success in clinical trials offers hope for long-term growth.
To see Spark’s full report on CRVO stock, click here.
More about CervoMed
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurological disorders.
Average Trading Volume: 203,077
Technical Sentiment Signal: Sell
Current Market Cap: $78.15M
Learn more about CRVO stock on TipRanks’ Stock Analysis page.